Skip to content Skip to footer

Novartis Inks a ~$1.44B Deal with Orionis to Advance Molecular Glue Therapies for Multiple Targets

Shots: Orionis Biosciences has entered into a multi-year collaboration with Novartis to discover & design molecular glue drugs for challenging therapeutic targets across multiple disease areas As per the deal, the companies will leverage Orionis’s Allo-Glue platform & AI-powered discovery engine to accelerate target & ligase profiling, as well as molecular glue optimization, enabling the…

Read more

PharmaShots Magazine-March-2026 Edition

Shots AI is transforming clinical trial oversight from periodic monitoring to continuous, real-time intelligence, enabling early detection of safety signals, protocol deviations, and operational risks while strengthening data integrity and patient protection. Advanced analytics and machine learning are powering predictive, risk-based monitoring, integrating data from decentralized trials, wearables, ePROs, and multiple clinical systems to prioritize…

Read more

20 AI Healthcare Companies of 2025  

Shots:  AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever  The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid…

Read more